Clinical reference Biomarker Directory
Back to directory

Coagulation Factor VII

Established

Factor VII deficiency is a rare bleeding disorder diagnosed by prolonged PT with normal aPTT.

Also known as FVII proconvertin
In plain language

Factor VII deficiency is a rare inherited bleeding disorder. A specialized clotting drug (recombinant factor VIIa) is officially approved to treat it, but interestingly, that same drug is used off-label far more often for other types of severe bleeding than for its approved use.

Biomarker & context

Factor VII is a vitamin K-dependent clotting protein synthesized in the liver with an unusually short half-life (4-6 hours); its deficiency is a rare inherited bleeding disorder affecting roughly 1 in 500,000 people.

What it indicates

Factor VII deficiency causes heterogeneous bleeding tendencies ranging from asymptomatic to severe, potentially fatal hemorrhage; diagnosis is based on prolonged prothrombin time (PT) with normal aPTT, confirmed by specific factor VII assay.

Diagnosis & clinical testing

Diagnosed via PT/aPTT screening followed by factor VII activity assay; acquired factor VII deficiency can also occur with liver disease, vitamin K deficiency, or oral anticoagulant use.

Guiding treatment

Recombinant activated factor VIIa (rFVIIa) is FDA-approved specifically for congenital factor VII deficiency bleeding, but a notable pattern exists: over 90% of all rFVIIa use nationally is off-label, for conditions like intracranial hemorrhage or cardiac surgery bleeding, well outside its approved indications.

Clinical significance

Its approved therapy (rFVIIa) is used far more often off-label for other bleeding emergencies than for its labeled indication.

References
  1. Sevenet, P. O., Kaczor, D. A., & Depasse, F. (2017). Factor VII Deficiency: From Basics to Clinical Laboratory Diagnosis. Clinical and Applied Thrombosis/Hemostasis.
  2. Medscape. Factor VII Deficiency: Practice Essentials.